5
Prosigna (PAM50)
Recommendation 1.15
➤ If a patient is postmenopausal and has breast cancer that is node-
negative, the clinician may use the Prosigna test to guide decisions for
adjuvant systemic chemotherapy. (Moderate recommendation; EB-I)
Recommendation 1.16
➤ If a patient is premenopausal, and has node-negative or node-positive
breast cancer the clinician should NOT use the Prosigna test to
guide decisions for adjuvant systemic chemotherapy. (Moderate
recommendation; IC-Ins)
Recommendation 1.17
➤ If a patient is postmenopausal and has node-positive breast cancer
with 1–3 positive nodes, the evidence is inconclusive to recommend
the use of Prosigna test to guide decisions for adjuvant endocrine and
chemotherapy. (Moderate recommendation; EB-I)
Recommendation 1.18
➤ If a patient has node-positive breast cancer with more than 3 positive
nodes, evidence on the clinical utility of routine use of Prosigna
test to guide decisions for adjuvant endocrine and chemotherapy is
insufficient to recommend its use. (Strong recommendation; IC-Ins)
Mammostrat
➤ There is insufficient evidence to recommend use of Mammostrat
to guide decisions about adjuvant endocrine and chemotherapy.
(Moderate recommendation; EB-I)
Breast Cancer Index (BCI)
➤ If a patient has ER-positive, HER2-negative, node-negative breast
cancer, the clinician may use the BCI to guide decisions for adjuvant
endocrine and chemotherapy. (Moderate recommendation; EB-I)
➤ If a patient has ER-positive, HER2-negative, node-positive breast
cancer, the clinician should NOT use the BCI to guide decisions about
adjuvant endocrine and chemotherapy. (Strong recommendation;
IC-Ins)
